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Colorectal cancer (CRC) is one of the most common cancers in the developed countries, and nearly 70% of patients
with CRCdevelop colorectal livermetastases (CRLMs). During the last decades, several scores have been proposed to
predict recurrence after CRLM resection. However, these risk scoring systems do not accurately reflect the prognosis
of these patients. Therefore, this investigation was designed to identify a proteomic profile in human hepatic tumor
samples to classify patientswithCRLMas “mild” or “severe” based on the 5-year survival. The studywas performed on
85 CRLM tumor samples. Firstly, to evaluate any distinct tumor proteomic signatures betweenmild and severe CRLM
patients, a training group of 57 CRLM tumor samples was characterized by surface-enhanced laser desorption/
ionization time-of-flightmass spectrometry, and a classification and regression tree (CART) analysis was subsequently
performed. Finally, 28 CRLM tumor samples were used to confirm and validate the results obtained. Based on all the
protein peaks detected in the training group, the CART analysis was generated, and four peaks were considered to be
themost relevant to construct a diagnostic algorithm. Indeed, themultivariatemodel yielded a sensitivity of 85.7%and
a specificity of 86.1%, respectively. In addition, the receiver operating characteristic (ROC) curve showed an excellent
diagnostic accuracy to discriminatemild fromsevereCRLMpatients (area under theROC: 0.903). Finally, the validation
process yielded a sensitivity and specificity of 68.8% and 83.3%, respectively. We identified a proteomic profile
potentially useful to determine the prognosis of CRLM patients based on the 5-year survival.
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making Europe.” CIBEREHD is funded by the Instituto de Salud Carlos III.
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Colorectal cancer (CRC) is the third most common cancer in the
United States in terms of incidence and mortality [1], and similar
results are also observed in other developed countries [2]. Nearly 70%
of patients with CRC develop colorectal liver metastases (CRLMs),
and 10% to 25% are diagnosed at the time of resection of the primary
tumor [3,4]. At present, surgical resection still remains the most
effective procedure to lengthen patient survival and is the only
curative treatment [5,6], with a 5-year survival rate of CRLM after
hepatic resection ranging from 30% to 60% [7]. Although some
patients are not surgical candidates, recent advances in chemotherapy,
radiofrequency ablation, and thermoablative methods have increased
the number of patients eligible for surgical resection [8]. Several scores
to predict recurrence after CRLM resection have been proposed to
improve the diagnosis and prognosis of these patients [9–12], with
the Fong score being one of the most known tools used for this
purpose. However, current risk scoring systems do not accurately
reflect the prognosis, and patient survival can be very similar even
with very different score values [13]. Thus, identification of a more
accurate system to predict patient survival is still of major relevance.
In this regard, the use of biomarkers that could, independently or
associated with classical prognostic indices, predict the neoplastic
evolution of the patient after surgical CRLM resection is a
well-defined strategy to enhance the reliability of predicting the
prognosis of CRLM [14,15]. Furthermore, biomarkers could
improve the selection of the optimal treatment for each patient to
enhance their prognosis.
In the current investigation, high-throughput proteomic techniques
were used to identify a potential protein panel in human hepatic tumor
samples to detect CRLMpatients with a poor prognosis. Ultimately, we
aimed to validate whether the protein panel profile identified could be
useful as a prognostic tool in CRLM patients.
Patients and Methods
Patients and Routine Laboratory Tests
Patients admitted to the Liver Transplantation Unit to undergo
CRLM resection from April 2005 to March 2012 were prospectively
considered for this study and were followed according to institutional
guidelines [16]. We obtained all clinical and pathological data from
the Liver Surgery Unit prospective database and clinical charts and
selected only the patients who could be included in a specific
prognostic group according to survival time. Thus, a total of 85
CRLMs were studied. Exclusion criteria were previous CRLM
resection or refusal to participate in the study. Chemotherapy
regimens used before hepatic resections were based on 5-fluorouracil
alone or associated with irinotecan or oxaliplatin according to local
protocols. Patients were classified based on their long-term outcome.
Thus, patients were considered as “mild” if their survival time was
longer than 5 years or “severe” if it was lower. Venous blood samples
from all CRLM patients were obtained after fasting. Extracted serum
samples were kept at −80°C, and several serum parameters, including
alanine transaminase, aspartate aminotransferase, albumin, bilirubin,
or creatinine, among others, were measured with the ADVIA 2400
Instrument (Siemens Healthcare Diagnostics, Tarrytown, NY). CEA
serum levels were determined using the ADVIA Centaur XP
Immunoassay System (Siemens Healthcare Diagnostics).
The design of the study was two-fold. Firstly, in a training set of 57
CRLM patients, we assessed whether the tissue proteomic profile ofthe mild patients differed from that of severe patients. Routine liver
and renal function tests were also analyzed in these patients.
Thereafter, liver tissue samples from 28 CRLM patients were also
collected and included in the blinded validation group to confirm the
results obtained.
Liver Resection of Metastatic Colorectal Cancer and Specimen
Collection
All metastatic tissue samples from patients undergoing curative
resection of CRLM were collected and immediately cryopreserved in
liquid nitrogen and kept until further analysis.
Hepatic Protein Extraction and Protein Fractionation from
Liver Homogenates
Approximately 50 mg of tumor hepatic tissue was ground to fine
powder in dry ice and solubilized by pestle homogenization in 500 μl
of urea buffer (9.5 M urea, 2% CHAPS, 1%DTT, 50 mMTris-HCl,
pH). Thereafter, tissue homogenates were incubated in a rotating
mixer for 1 hour at 4°C, and insoluble material was removed by
centrifugation (16,000 ×g, 4°C for 15 minutes). Afterwards, samples
were aliquoted and kept at −80°C until protein fractionation was
performed. In short, samples were fractionated by pH using a 96-well
filtration plate (Pall Corp., Port Washington, NY) with 200 μl of a
macro-prep high Q anion exchange support (Bio-Rad Laboratories,
Hercules, CA) in each well. Flow-through was discarded by vacuum
filtration. Subsequently, each well was washed twice with 200 μl of
distilled water and equilibrated with 200 μl of rehydration buffer (50
mM Tris-HCl, pH). Wells were incubated for 1 hour at room
temperature. Thereafter, each well was equilibrated three times with
200 μl of an equilibration buffer [1 M urea, 0.2% (w/v) CHAPS, 50
mM Tris-HCl, pH]. Prior to fractionation, 20 μl of tissue
homogenates was mixed with 30 μl of urea buffer [9 M urea, 2%
(w/v) CHAPS, 50 mM Tris-HCl, pH] in a 96-well V-bottom plate
for 20 minutes at 4°C in a horizontal orbital microplate shaker.
Samples were then diluted with 50 μl of equilibration buffer,
transferred to each well, and incubated for 30 minutes at 4°C with
shaking. All samples were eluted in a stepwise manner by altering the
pH of the wash buffer. Six different fractions were obtained.
Flow-through was collected by vacuum filtration into V-bottom
microplates, and all were stored at −80°C until proteomic analysis.
Proteomic Processing of Hepatic Tissue Samples
Protein profiling was analyzed by surface-enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry (SELDI-TOF-MS)
using the eight-spot format ProteinChip array (Bio-Rad). In a
preliminary study to optimize the experimental conditions, two
pooled samples from mild CRLM patients and severe CRLM patients
were fractionated, and the six fractions obtained were loaded onto
three different types of ProteinChip arrays that had different protein
binding affinity; weak cation exchange arrays (CM10), immobilized
metal affinity chromatography arrays (IMAC30), and hydrophobic/
reverse-phase arrays (H50). The resulting protein profile from each
pool was compared, and the fraction number 3 using the CM10
ProteinChip array showed the highest number of peaks detected, the
highest total signal intensity, and the major differences between
groups when compared with all other fractions and ProteinChip
arrays. Thus, fraction number 3 and CM10 ProteinChip array were
selected for the subsequent studies. Prior to sample loading, spots
were equilibrated twice with 200 μl of a sodium acetate buffer (0.1 M




Group (n = 57)
Validation
Group (n = 28)
P Value
Gender (M/F) 65/20 43/14 22/6 NS
Age (years) 65.0 ± 0.9 65.2 ± 1.1 64.6 ± 1.8 NS
Node positive in primary tumor [n (%)] 58 (68.2%) 41 (71.9%) 17 (60.7%) NS
Disease-free interval b12 months [n (%)] 58 (68.2%) 43 (75.4%) 15 (53.6%) NS
CEA (ng/ml) 34.2 ± 8.3 43.4 ± 12.2 15.8 ± 3.8 b.05
CEA b200 ng/ml 84 (94.1%) 52 (91.2%) 28 (100%) NS
Number of tumors 2.7 ± 0.3 2.5 ± 0.2 3.0 ± 0.6 NS
Multinodularity [n (%)] 56 (65.9%) 38 (66.7%) 18 (64.3%) NS
Tumor size (cm) 3.0 ± 0.2 2.6 ± 0.2 3.9 ± 0.6 b.05
Largest tumor N5 cm [n (%)] 10 (11.8%) 5 (8.8%) 5 (17.9%) NS
Fong score 2.2 ± 0.9 2.3 ± 0.1 1.9 ± 0.2 NS
Fong score ≤2 (low risk) 51 32 19 –
Fong score N3 (high risk) 34 25 9 –
NS, not significant.
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was mixed with 60 μl of the sodium acetate buffer, and this mixture
(100 μl) was subsequently loaded randomly and incubated for 1 hour
on a shaker at room temperature. Afterward, CM10 ProteinChip
arrays were washed three times with 200 μl of the sodium acetate
buffer for 5 minutes on a shaker at room temperature and twice with
deionized water to remove unbound proteins. Thereafter, arrays were
air-dried, and 1 μl of energy-absorbing matrix (saturated sinapinic
acid in an aqueous solution containing 50% acetonitrile and 0.5%
trifluoroacetic acid) was added twice to each spot. The surface was
allowed to air dry between each application. Finally, ProteinChips
were read in the ProteinChip PBS II reader (Bio-Rad).
Data Acquisition and Analysis
All data were processed as described elsewhere [17]. Briefly, each
spot was analyzed at three different energy laser intensities: 2500 nJ,
3000 nJ, and 3500 nJ, and the mass-to-charge ratio (m/z) was set
from m/z 1000 to 25,000 for the low-energy laser intensity, between
m/z 2500 and 200,000 for the medium-energy laser intensity, and
from m/z 5000 to 200,000 for the high-energy laser intensity. In
addition, peak resolution was focused atm/z 5000, 12,000, or 19,000
according to low-, medium-, or high-energy laser intensity,
respectively.
Protein spectra were calibrated using two different external
calibration standards (all-in-one peptide standard and all-in-one
protein standard, Bio-Rad Laboratories), and they were subsequently
normalized by the average total ion current across the group. To
minimize outliers, all spectra differing by at least twice the standard
deviation from the mean were deleted. Baseline adjustments, peak
selection parameters such as the minimal signal-to-noise ratio, valley
depth, and m/z error were also defined as described previously [17].
Afterward, all protein peak clusters automatically identified were
manually verified. Relabeling, removal, or addition of peaks was
performed when necessary.
Statistical Analysis
Statistical analyses were performed by the nonparametric
Mann-Whitney U test or the Fisher test when appropriate. Results
are expressed as mean ± SE, and P values lower than .05 were
considered significant. All statistical clinical analyses were performed
with the PASW Statistical Package Version 18.0 for Windows (SPSS,
Chicago, IL). Quantitative proteomic data were analyzed using
GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).
Finally, a classification and regression tree (CART) analysis was
performed using the Biomarker Patterns (Bio-Rad) to detect the
protein peaks with the greatest contribution to discriminate both
groups.
Ethical Approval
We obtained written informed consent from all patients included
in the study when they were proposed for surgery, and the
investigation was approved by the Investigation and Ethics
Committee of the Hospital Clinic of Barcelona following the ethical
guidelines of the 1975 Declaration of Helsinki.
Results
The main demographic variables of the patients included in the
training set are summarized in Table 1. Of note is that nearly 40% of
the CRLM patients included in the training group showeddiscrepancies between their theoretical risk factor, obtained by Fong's
prognostic scoring system, and their actual survival.
Reproducibility of SELDI-TOF-MS Protein Profiling in
Hepatic Tumor Samples
Experiments combining hepatic protein extraction and protein
fractionation were performed to evaluate intraexperiment variation. A
pooled hepatic tumor sample from the 27 CRLM patients included in
the training group was obtained and treated as the other samples.
Basically, it was processed independently 15 times and subsequently
measured in a CM ProteinChip array (Bio-Rad). Finally, the
SELDI-TOF-MS spectra were accurately analyzed. Based on the
protein peaks detected in the m/z 1000 to 25,000 range, the
intraassay (spot to spot) maximum coefficient of variation (CV) was
44.70% for peak intensity and 0.04% for mass accuracy. In addition,
the day-to-day variation was also evaluated. The pooled hepatic tumor
sample was processed and analyzed independently in three different
days, and the maximum CV for peak intensity and mass accuracy was
39.56% and 0.12%, respectively.
Differential Proteomic Profiles Between Mild CRLM Patients
and Severe CRLM Patients
Twenty-one severe CRLM patients and 36 mild CRLM patients
constituted the training set (Table 1). Two technical replicates were
analyzed for each sample. We detected 118 protein peaks over a range
of 1 to 25 kDa. Among these, only proteins showing a peak intensity
of at least 2 μA and a m/z standard deviation below 11 were
considered for further analysis. Moreover, and based on the results
obtained in the pooled hepatic tumor sample, proteins with a CV
greater than 30% for peak intensity and 0.02% for mass accuracy
were also excluded. According to this protein peak exclusion strategy,
39 protein peaks were selected (see supplementary data 1). Figure 1
shows the protein spectra obtained by SELDI-TOF-MS which
ranged between m/z 2000 and 11,000 in these subjects. Several
protein differences were detected in the hepatic tumor proteomic
profile between the two groups. In particular, three protein peaks
with m/z values of 2726, 3251, and 9950 and shown in the Figure 1
as A, B, and C, respectively, were the most statistically significant.
The intensity of the m/z 2726 and m/z 3251 protein peaks was
downregulated in mild compared with severe CRLM patients. On the
other hand, the m/z 9950 protein peak was upregulated in the mild
group (Table 2). However, no single protein peak was able to clearly
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Figure 1. Differential proteomic signature of mild and severe CRLM patients. Two segments of the SELDI-TOF-MS spectra ranging from
m/z 2000 tom/z 5500 and fromm/z 9500 tom/z 11,000 of all the tumor tissue samples from CRLM patients comprising the training group.
The upper figure shows all the overlapped spectra of mild CRLM patients (n= 36). The bottom figure shows the spectra of severe CRLM
patients (n = 21). Arrows show the three protein peaks with statistical significance between groups. Upper letters correspond to the
peptide identification peak noted in Table 2.
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Analysis
To measure the impact of all the protein peaks detected and
identify those with the greatest discriminatory power, a nonparamet-
ric procedure was used based on the normalized data obtained by
SELDI-TOF-MS. A CART with five terminal nodes was generated,
and the combination of four different protein peaks was considered as
the most relevant to construct the diagnostic algorithm (Figure 2A).
The protein peaks which best differentiated mild from severe
CRLM patients were m/z 2726, m/z 2761, m/z 3110, and m/z
4939. Figure 2B shows the proteomic spectra of these protein peaks.
The classification tree yielded a sensitivity of 85.7%, a specificity of
86.1%, and a negative predictive value (NPV) and a positiveTable 2. Main Characteristics of the Protein Peaks Displaying Statistically Different Intensities on
Comparing Mild and Severe CRLM Patients
Intensity (μA)
Peptide m/z (Da) Mild Severe P Value
A 2726 59.0 ± 8.8 87.6 ± 12.6 .04
B 3251 26.2 ± 2.9 34.3 ± 3.3 .03
C 9950 22.7 ± 3.0 13.8 ± 2.2 .04
Statistical analysis was performed by Mann-Whitney U test. Results are given as mean ± SE.predictive value (PPV) of 91.2% and 78.3%, respectively. To further
test the diagnostic accuracy of the classification tree in CRLM
patients, a receiver operating characteristic (ROC) curve was
constructed. Figure 3 shows the excellent diagnostic accuracy of the
classification tree to differentiate mild from severe CRLM patients
(area under the ROC: 0.903).
CART Analysis Assessment in the Validation Group
To confirm that the classification tree could be used as a prognostic
tool, an independent group of 28 CRLM patients was tested as the
blinded validation set. All hepatic tumor samples were collected and
processed as described in the training group. As noticed in the MS
spectra, very similar patterns were observed in the validation group
when compared with the training set (Figure 4). In particular, the
four protein peaks used to construct the classification tree showed an
extremely high mass accuracy. The maximum m/z error was detected
in the 3.1-kDa protein peak, despite the mass accuracy being below
505 ppm. After performing the CART analysis, 15 CRLM patients
were clustered as “mild,” whereas 13 were considered “severe.”
Subsequently, the proteomic data were compared with the clinical
outcome of each subject. The principal demographic characteristics of
the patients included in the validation set are shown in Table 1.
Only two mild patients were misclassified, whereas this figure was
five in the group of severe patients. These results yielded a sensitivity
Figure 2. CART analysis to classify and differentiate mild from severe CRLM patients based on the proteomic profile obtained from the
hepatic tumor samples. (A) Decision tree model for the classification of liver tumor samples frommild and severe CRLM patients. Node 0
(the upper white square of the decision tree) is known as the root node, which indicates the starting point of the decision tree construction
and included all the patients. This node is divided based on the intensity value of the m/z 2726. If the intensity is lower than 63 μA, then
these patients are put in a primary node (left white square) and are subsequently split based on the intensity value of the m/z 4939.
However, if the intensity is higher than this cutoff (63 μA), patients are placed in the right primary node (white square) and further split
based on them/z 2761 protein peak. This procedure is subsequently repeated until a terminal node is reached (blue and red squares). As
observed, the majority of mild CRLM patients are clustered in the green terminal nodes, whereas severe CRLM patients are grouped in
the red terminal node. Only three severe CRLM patients and five mild CRLM patients were misclassified.(B) Two sections of the
SELDI-TOF-MS spectra. The first ranges from m/z 2650 to 3250, and the second is comprised between m/z 4850 and 5050. The upper
figure shows all the overlapped spectra of the mild CRLM patients (n = 36). The bottom figure shows the spectra of the severe CRLM
patients (n = 21). Arrows indicate the four protein peaks used to construct the diagnostic algorithm based on the CART analysis.
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as well as the PPV and the false discovery rate (1 − PPV) were
also determined (Figure 4). The figures were 66.7%, 84.6%, and
15.4%, respectively.Discussion
Early detection of CRLM patients with poor prognosis is
fundamental to improve therapeutic interventions and thus increase



















Figure 3. Diagnostic accuracy of the CART analysis. Diagnostic
accuracy of the classification tree to differentiate mild and severe
CRLM patients. The area under the ROC obtained from the CART
analysis was 0.903.
450 Metastatic Tissue Proteomic Profiling Marfà et al. Translational Oncology Vol. 9, No. 5, 2016resection is mainly based on several clinical indicators [9,10], with
tumor-free interval being one of the most determinant. Indeed, it is
known that the development of neoplastic recurrence within the first
year after liver resection is associated with a worse outcome [10].
However, mortality and the potential degree of severity based on all
these different risk scoring systems are not always closely related [13],
as other variables may influence the prognosis of these patients. In
this study, we observed that there was not a clear correlation between

















1,000 validation group (n=28)
Figure 4. SELDI-TOF-MS proteomic profile and diagnostic tests from
from the 28 CRLM patients that comprised the blinded validation grou
is comprised between m/z 9500 and 11,000. As observed, the prote
insert shows the diagnostic tests (sensitivity, specificity, NPV, and
diagnostic algorithm.the survival time. Particularly, 22 of the 57 CRLM patients included
in the training group showed discrepancies. Therefore, the search
for new tools capable of predicting survival still remains an open
challenge.
In the present study, we used a high-throughput proteomic
technique to unveil a differential proteomic signature among CRLM
patients based on their survival time. SELDI-TOF-MS, which is
based on matrix-assisted laser desorption/ionization TOF-MS, has
been used as a proteomic strategy in several studies to detect and
identify potential biomarkers related to many different diseases
including colorectal cancer [17–21]. It combines a solid-phase
chromatographic surface with TOF-MS that enables the analysis of
crude samples such as tissue lysate, saliva, serum, urine, etc. Sample
fractionation is performed previously to reduce sample complexity,
thus enabling the detection of low-abundance proteins. In the current
study, tumor tissue samples were fractionated by anion exchange
chromatography, and the third eluate was analyzed by MS. The
solid-phase chromatographic surface was selected based on the highest
number of protein peaks detected and the highest total signal
intensity analyzed in a preliminary study. Using this procedure, we
detected 118 protein peaks over a range of 1 to 25 kDa. Three protein
peaks with m/z values of 2726, 3251, and 9950 were statistically
significant. However, none of these peaks clearly differentiated mild
from severe CRLM patients. Therefore, we performed a CART
analysis which showed that the expression of four different protein
peaks was the most relevant protein combination to classify these
patients according to survival. Among these peaks, only the one
located at m/z 2726 was statistically significant. The other three
protein peaks selected in the CART analysis did not coincide with any
of those that were statistically significant. This feature is not
surprising because the protein peaks which best separate the different
smaller subsets obtained during the CART analysis are not necessarily
the same as those that are globally statistically significant between
both groups.m/z5,000 10,000 11,000
the validation group. Two portions of the SELDI-TOF-MS spectra
p. The first segment ranges fromm/z 2000 to 5500, and the second
omic signature was very similar to that of the training group. The
PPV) performed to further strengthen the clinical relevance of the
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patients [22,23]. These investigations are mainly related to predicting
neoplastic recurrence after CRLM resection and metachronous liver
metastasis from colorectal cancer in serum samples. However, none of
these investigations has explored the tumor proteomic signature to
predict survival. Therefore, we first performed a proteomic analysis in
57 liver tumor samples from CRLM patients to assess whether there is
a differential proteomic profile between patients with a greater or less
than 5-year survival. As mentioned above, CART analysis revealed
four protein peaks enabling the classification of CRLM patients and
thus their outcome. These results were further validated in a new
group of CRLM patients possessing similar clinical characteristics to
those observed in the training group. Of note was that the specificity
and the PPV values obtained in the validation set (83.3% and 84.6%,
respectively) were very similar to those previously determined in the
training group. However, those corresponding to sensitivity and NPV
were lower (68.8% and 66.7%, respectively).
CART analysis has proven to be a relevant strategy to predict the
response of cancer patients to treatment [24] and the prognosis of
disorders other than colorectal cancer, including chronic myelomo-
nocytic leukemia or pulmonary complications after lung resection
[25,26]. One of the major advantages of CART analysis is the simple
and intuitive nature of this algorithm. In comparison to traditional
regression methods, in which the prognostic score is obtained as a
weighted average of several biochemical and clinical factors, CART
classifies patients into groups based on simple combinations of the
patients' characteristics [27]. In the current investigation, CART
analysis resulted in the identification of 4 protein peaks able to
discriminate CRLM patients with a survival time of longer than 5
years from those with shorter survival periods. Therefore, by using the
algorithm obtained, it is possible to predict the survival time of these
subjects at the time of tumor resection with a remarkable sensitivity
and specificity.
A major issue emerging from these results is related to the
identification of the different peaks included in the CART analysis.
However, although this information could be very relevant to better
understand the mechanisms involved in colorectal carcinoma
metastases, the identification of these peaks would not result in an
improvement in the performance of the algorithm as a prognostic
indicator of survival.
In conclusion, the results presented in the current investigation
indicate that proteomic analysis of liver tumor samples from CRLM
patients may be useful to determine their 5-year survival. The use of
a classification tree allowed the identification of four protein
peaks with clear clinical relevance. This finding was validated in
another set of CRLM patients, further strengthening its diagnostic
value. These results, therefore, set the rationale to perform future
studies focused on the identification of these four protein peaks. In
addition, they could provide valuable insight into the altered
molecular signaling pathways that are involved in the survival of
patients with CRLM.
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